Emerging biomarkers, such as BRCA1 and BRCA2 mutations, indicate breast cancer risk and inform preventive strategies and therapeutic choices.44 Comprehensive molecular profiling has the potential to uncover additional targets and refine patient stratification, facilitating personalised medicine approaches in breast cancer management.45 This evidence concerns the gene BRCA2 and breast carcinoma.